Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)
© 2024 European Society of Cardiology..
Implantable devices form an integral part of the management of patients with heart failure (HF) and provide adjunctive therapies in addition to cornerstone drug treatment. Although the number of these devices is growing, only few are supported by robust evidence. Current devices aim to improve haemodynamics, improve reverse remodelling, or provide electrical therapy. A number of these devices have guideline recommendations and some have been shown to improve outcomes such as cardiac resynchronization therapy, implantable cardioverter-defibrillators and long-term mechanical support. For others, more evidence is still needed before large-scale implementation can be strongly advised. Of note, devices and drugs can work synergistically in HF as improved disease control with devices can allow for further optimization of drug therapy. Therefore, some devices might already be considered early in the disease trajectory of HF patients, while others might only be reserved for advanced HF. As such, device therapy should be integrated into HF care programmes. Unfortunately, implementation of devices, including those with the greatest evidence, in clinical care pathways is still suboptimal. This clinical consensus document of the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) describes the physiological rationale behind device-provided therapy and also device-guided management, offers an overview of current implantable device options recommended by the guidelines and proposes a new integrated model of device therapy as a part of HF care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
European journal of heart failure - 26(2024), 2 vom: 25. Feb., Seite 483-501 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 27.03.2024 Date Revised 11.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ejhf.3150 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367598973 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367598973 | ||
| 003 | DE-627 | ||
| 005 | 20240411232252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ejhf.3150 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM367598973 | ||
| 035 | |a (NLM)38269474 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mullens, Wilfried |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 European Society of Cardiology. | ||
| 520 | |a Implantable devices form an integral part of the management of patients with heart failure (HF) and provide adjunctive therapies in addition to cornerstone drug treatment. Although the number of these devices is growing, only few are supported by robust evidence. Current devices aim to improve haemodynamics, improve reverse remodelling, or provide electrical therapy. A number of these devices have guideline recommendations and some have been shown to improve outcomes such as cardiac resynchronization therapy, implantable cardioverter-defibrillators and long-term mechanical support. For others, more evidence is still needed before large-scale implementation can be strongly advised. Of note, devices and drugs can work synergistically in HF as improved disease control with devices can allow for further optimization of drug therapy. Therefore, some devices might already be considered early in the disease trajectory of HF patients, while others might only be reserved for advanced HF. As such, device therapy should be integrated into HF care programmes. Unfortunately, implementation of devices, including those with the greatest evidence, in clinical care pathways is still suboptimal. This clinical consensus document of the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) describes the physiological rationale behind device-provided therapy and also device-guided management, offers an overview of current implantable device options recommended by the guidelines and proposes a new integrated model of device therapy as a part of HF care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Device therapy | |
| 650 | 4 | |a Heart failure | |
| 700 | 1 | |a Dauw, Jeroen |e verfasserin |4 aut | |
| 700 | 1 | |a Gustafsson, Finn |e verfasserin |4 aut | |
| 700 | 1 | |a Mebazaa, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Steffel, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Witte, Klaus K |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Linde, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Vernooy, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Anker, Stefan D |e verfasserin |4 aut | |
| 700 | 1 | |a Chioncel, Ovidiu |e verfasserin |4 aut | |
| 700 | 1 | |a Milicic, Davor |e verfasserin |4 aut | |
| 700 | 1 | |a Hasenfuß, Gerd |e verfasserin |4 aut | |
| 700 | 1 | |a Ponikowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a von Bardeleben, Ralph Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Koehler, Friedrich |e verfasserin |4 aut | |
| 700 | 1 | |a Ruschitzka, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Damman, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Schwammenthal, Ehud |e verfasserin |4 aut | |
| 700 | 1 | |a Testani, Jeffrey M |e verfasserin |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e verfasserin |4 aut | |
| 700 | 1 | |a Böhm, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Cowie, Martin R |e verfasserin |4 aut | |
| 700 | 1 | |a Dickstein, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Jaarsma, Tiny |e verfasserin |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e verfasserin |4 aut | |
| 700 | 1 | |a Volterrani, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Thum, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Adamopoulos, Stamatis |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen-Solal, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Moura, Brenda |e verfasserin |4 aut | |
| 700 | 1 | |a Rakisheva, Amina |e verfasserin |4 aut | |
| 700 | 1 | |a Ristic, Arsen |e verfasserin |4 aut | |
| 700 | 1 | |a Bayes-Genis, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Van Linthout, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Tocchetti, Carlo Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Savarese, Gianluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Skouri, Hadi |e verfasserin |4 aut | |
| 700 | 1 | |a Adamo, Marianna |e verfasserin |4 aut | |
| 700 | 1 | |a Amir, Offer |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Mehmet Birhan |e verfasserin |4 aut | |
| 700 | 1 | |a Simpson, Maggie |e verfasserin |4 aut | |
| 700 | 1 | |a Tokmakova, Mariya |e verfasserin |4 aut | |
| 700 | 1 | |a González, Arantxa |e verfasserin |4 aut | |
| 700 | 1 | |a Piepoli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Seferovic, Petar |e verfasserin |4 aut | |
| 700 | 1 | |a Metra, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Coats, Andrew J S |e verfasserin |4 aut | |
| 700 | 1 | |a Rosano, Giuseppe M C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of heart failure |d 1999 |g 26(2024), 2 vom: 25. Feb., Seite 483-501 |w (DE-627)NLM106698575 |x 1879-0844 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:2 |g day:25 |g month:02 |g pages:483-501 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ejhf.3150 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 2 |b 25 |c 02 |h 483-501 | ||